ReviewImmunogenetics2023
Role of T cells in severe COVID-19 disease, protection, and long term immunity.
Review in Immunogenetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 54 citations in OpenAlex.
- Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Article
- Informing the Value of "Boosting" Immunocompetent Adults based on Immune Responses Among US Service Members to SARS-CoV-2 Variants in Late 2024.Open forum infectious diseases · 2026Article
- T-cell responses to highly conserved SARS-CoV-2 epitopes in Hispanic Americans receiving an mRNA COVID-19 vaccine.Human vaccines & immunotherapeutics · 2025Article
- Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.Vaccines · 2025Review
- Myeloid-Driven Immune Suppression Subverts Neutralizing Antibodies and T Cell Immunity in Severe COVID-19.Journal of medical virology · 2025Article
- Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19.NPJ vaccines · 2025Article
- The Role of Memory T-Cell Mediated Immunity in Long-term COVID-19: Effects of Vaccination Status.Iranian journal of medical sciences · 2025Review
- Article
- Poor vaccine responders mask the true trend in vaccine effectiveness against progression to severe disease.Vaccine · 2025Article
- Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune function.PloS one · 2025Article
- Durability of Functional SARS-CoV-2-Specific Immunological Memory and T Cell Response up to 8-9 Months Postrecovery From COVID-19.Journal of immunology research · 2025Article
- The effect of COVID-19 and sex differences on natural killer cell cytotoxicity.Frontiers in cellular and infection microbiology · 2025Article
- Bronchoalveolar lavage single-cell transcriptomics reveals immune dysregulations driving COVID-19 severity.PloS one · 2025Article
- B-Lightning: using bait genes for marker gene hunting in single-cell data with complex heterogeneity.Briefings in bioinformatics · 2024Article
- COVID-19 vaccine updates for people under different conditions.Science China. Life sciences · 2024Review
- T-Cell Phenotypes and Systemic Cytokine Profiles of People Living with HIV Admitted to Hospital with COVID-19.Microorganisms · 2024Article
- Article
- Immune Profile in COVID-19: Unveiling TInternational journal of molecular sciences · 2024Article
- Aberrant innate immune profile associated with COVID-19 mortality in Pretoria, South Africa.Clinical immunology (Orlando, Fla.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with SARS-CoV-2 causes wide range of disease severities from asymptomatic to life-threatening disease. Understanding the contribution of immunological traits in immunity against SARS-CoV-2 and in protection against severe COVID-19 could result in effective measures to prevent development of severe disease. While the role of cytokines and antibodies has been thoroughly studied, this is not the case for T cells. In this review, the association between T cells and COVID-19 disease severity and protection upon reexposure is discussed. While infiltration of overactivated cytotoxic T cells might be harmful in the infected tissue, fast responding T cells are important in the protection against severe COVID-19. This protection could even be viable in the long term as long-living memory T cells seem to be stabilized and mutations do not appear to have a large impact on T cell responses. Thus, after vaccination and infections, memory T cells should be able to help prevent onset of severe disease for most cases. Considering this, it would be useful to add N or M proteins in vaccinations, alongside the S protein which is currently used, as this results in a broader T cell response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.